Company Overview

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of targeted therapies for oncology indications. The company operates within the biotechnology and oncology drug development industries, with a primary emphasis on addressing cancers with high unmet medical need through novel molecular mechanisms. Its core asset targets glycogen synthase kinase-3 beta (GSK-3β), a signaling protein implicated in tumor growth, immune evasion, and treatment resistance across multiple cancer types.

The company’s lead product candidate, elraglusib (9-ING-41), is a selective small-molecule GSK-3β inhibitor being evaluated in multiple Phase 1 and Phase 2 clinical trials, both as a monotherapy and in combination with chemotherapy, targeted agents, and immuno-oncology drugs. Actuate Therapeutics was founded in 2015 and has evolved from preclinical research into a multi-study clinical development organization, advancing its pipeline through collaborations with academic institutions and government-supported research networks. Public information is inconsistent regarding the company’s trading status under the ticker “ACTU”; data inconclusive based on available public sources.

Business Operations

Actuate Therapeutics’ operations are centered on oncology drug research and clinical development, with revenue generation not yet established due to its clinical-stage status. The company’s activities primarily involve preclinical research, clinical trial execution, regulatory engagement, and intellectual property management related to elraglusib (9-ING-41). Clinical programs have included investigator-sponsored and company-sponsored trials in indications such as pancreatic cancer, glioblastoma, lymphoma, and metastatic breast cancer.

Operations are conducted through internal research management and external partnerships, including collaborations with U.S. cancer centers and cooperative clinical trial groups. The company does not report commercial manufacturing or sales operations, and there is no verified evidence of marketed products. Actuate Therapeutics operates primarily in the United States, with international clinical trial participation where applicable.

Strategic Position & Investments

Strategically, Actuate Therapeutics is focused on advancing elraglusib (9-ING-41) through combination-based oncology trials, positioning the compound as a potential enhancer of existing standard-of-care therapies. The company’s development strategy emphasizes mechanistic differentiation by targeting GSK-3β, which is less directly addressed by currently approved oncology drugs. This positioning is intended to support applicability across multiple tumor types and therapeutic regimens.

The company has received non-dilutive funding support and research backing through collaborations involving U.S. government-affiliated cancer research programs, including trials conducted within National Cancer Institute–supported networks. There is no publicly verified record of major acquisitions or a diversified subsidiary structure; the company’s investment focus remains concentrated on its lead clinical asset. Information regarding additional pipeline assets beyond elraglusib is limited; data inconclusive based on available public sources.

Geographic Footprint

Actuate Therapeutics is headquartered in the United States, with its primary corporate and research activities based in Colorado. Its operational footprint is predominantly domestic, reflecting its status as a clinical-stage biotechnology company without commercial infrastructure. Clinical trials have been conducted across multiple U.S. states through partnerships with academic medical centers and oncology research institutions.

Internationally, the company’s presence is primarily indirect, achieved through multinational clinical trial sites and global scientific collaboration rather than owned facilities or subsidiaries. There is no verified evidence of significant standalone operations in Europe, Asia-Pacific, or other regions, though patients outside the United States have been included in certain clinical studies.

Leadership & Governance

Actuate Therapeutics was founded by Daniel Schmitt, who continues to guide the company’s strategic direction. Leadership is oriented toward translational science, disciplined clinical development, and partnership-driven execution. The governance approach emphasizes advancing a focused pipeline while leveraging external expertise to manage capital efficiency and scientific risk.

Key members of the leadership team include:

• Daniel Schmitt – Chief Executive Officer
• Andrew G. Roberts, MD – Chief Medical Officer
• David Flood – Chief Operating Officer

Publicly available information on board composition and additional executive roles is limited; data inconclusive based on available public sources.